Surgeons need to adapt to evolving treatments for unresectable colorectal liver metastases (uCRLM) that significantly impact outcomes.

• Advances in systemic therapy combined with liver-directed strategies have broadened curative options, using techniques like ablation and transarterial therapies.
• Patient selection now focuses on tumor biology and therapy response, moving away from strict anatomy-based criteria.

Early referral to specialized centers is critical for maximizing treatment effectiveness.

• New interventions like combined portal and hepatic vein embolization offer promising avenues for patient management.